QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.056879v1 308/1/268    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thurmond, R. L. Articles by Karlsson, L. Search for Related Content PubMed PubMed Citation Articles by Thurmond, R. L. Articles by Karlsson, L.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., San Diego, California

Cathepsin S is considered crucial for normal presentation of major histocompatibility complex (MHC) class II-restricted antigens by antigen presenting cells to CD4⁺ T cells. It is a key enzyme for the degradation of the class II-associated invariant chain, a process that is required for effective antigen loading of class II molecules. Here, we report a selective, orally available, high-affinity cathepsin S inhibitor, 1-[3-[4-(6-Chloro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridine. (JNJ 10329670), that represents a novel class of immunosuppressive compounds. JNJ 10329670 is a highly potent (K_i of 30 nM), nonpeptidic, noncovalent inhibitor of human cathepsin S, but it is much less active against the mouse, dog, monkey, and bovine enzymes. The compound is inactive against other proteases, including the closely related cathepsins L, F, and K. This selectivity makes JNJ 10329670 an excellent tool for exploring the role of cathepsin S in human systems. Treatment of human B cell lines and primary human dendritic cells with JNJ 10329670 resulted in the accumulation of the p10 fragment of the invariant chain (IC₅₀ of 1 µM). In contrast, inhibition of invariant chain proteolysis was much less effective in a human monocytic cell line, suggesting that other enzymes may degrade the invariant chain in this cell type. JNJ 10329670 was shown to block the proteolysis of the invariant chain in vivo by using immunocompromised mice injected with human peripheral blood mononuclear cells (PBMCs). Furthermore, this inhibitor blocks the presentation of tetanus toxoid and giant ragweed by human PBMCs. The properties of JNJ 10329670 make it a candidate for immunosuppressive therapy of allergies and autoimmune diseases.

Address correspondence to: Dr. Robin L. Thurmond, 3210 Merryfield Row, San Diego, CA 92121. E-mail: rthurmon{at}prdus.jnj.com

This article has been cited by other articles:

				A. Sa-Nunes, A. Bafica, L. R. Antonelli, E. Y. Choi, I. M. B. Francischetti, J. F. Andersen, G.-P. Shi, T. Chavakis, J. M. Ribeiro, and M. Kotsyfakis The Immunomodulatory Action of Sialostatin L on Dendritic Cells Reveals Its Potential to Interfere with Autoimmunity J. Immunol., June 15, 2009; 182(12): 7422 - 7429. [Abstract] [Full Text] [PDF]

				T.-I Lin, O. Lenz, G. Fanning, T. Verbinnen, F. Delouvroy, A. Scholliers, K. Vermeiren, A. Rosenquist, M. Edlund, B. Samuelsson, et al. In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1377 - 1385. [Abstract] [Full Text] [PDF]

				S. W. Howland and K. D. Wittrup Antigen Release Kinetics in the Phagosome Are Critical to Cross-Presentation Efficiency J. Immunol., February 1, 2008; 180(3): 1576 - 1583. [Abstract] [Full Text] [PDF]